DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,890,415 | +2.6% | 35,834 | -0.7% | 0.08% | +6.7% |
| Q2 2023 | $8,661,120 | +93594.5% | 36,088 | -1.6% | 0.08% | -9.6% |
| Q1 2023 | $9,244 | -7.8% | 36,678 | -2.9% | 0.08% | -9.8% |
| Q4 2022 | $10,021 | -99.9% | 37,755 | +0.2% | 0.09% | -6.1% |
| Q3 2022 | $9,732,000 | +0.8% | 37,677 | -1.0% | 0.10% | +6.5% |
| Q2 2022 | $9,652,000 | -16.7% | 38,072 | -3.7% | 0.09% | -2.1% |
| Q1 2022 | $11,592,000 | -13.2% | 39,519 | -2.7% | 0.09% | -9.6% |
| Q4 2021 | $13,357,000 | +3.3% | 40,598 | -4.4% | 0.10% | -7.1% |
| Q3 2021 | $12,932,000 | -14.6% | 42,478 | -24.7% | 0.11% | -14.5% |
| Q2 2021 | $15,136,000 | +0.5% | 56,401 | -15.7% | 0.13% | -3.7% |
| Q1 2021 | $15,056,000 | +4.7% | 66,890 | +3.3% | 0.14% | -2.2% |
| Q4 2020 | $14,377,000 | +2.5% | 64,724 | -0.7% | 0.14% | -9.2% |
| Q3 2020 | $14,032,000 | +18.6% | 65,166 | -2.6% | 0.15% | +10.9% |
| Q2 2020 | $11,830,000 | +53.5% | 66,901 | +20.1% | 0.14% | +34.0% |
| Q1 2020 | $7,707,000 | -8.2% | 55,689 | +1.8% | 0.10% | +17.0% |
| Q4 2019 | $8,394,000 | -1.0% | 54,685 | -6.8% | 0.09% | -6.4% |
| Q3 2019 | $8,476,000 | -2.4% | 58,686 | -3.4% | 0.09% | -4.1% |
| Q2 2019 | $8,685,000 | +4.9% | 60,769 | -3.1% | 0.10% | +3.2% |
| Q1 2019 | $8,279,000 | +26.8% | 62,711 | -0.9% | 0.10% | +15.9% |
| Q4 2018 | $6,527,000 | -4.7% | 63,288 | +0.4% | 0.08% | +10.8% |
| Q3 2018 | $6,852,000 | +13.9% | 63,056 | +3.5% | 0.07% | +8.8% |
| Q2 2018 | $6,014,000 | -7.5% | 60,945 | -8.2% | 0.07% | -6.8% |
| Q1 2018 | $6,501,000 | -3.0% | 66,393 | -8.0% | 0.07% | +1.4% |
| Q4 2017 | $6,700,000 | +6.3% | 72,184 | -1.7% | 0.07% | 0.0% |
| Q3 2017 | $6,300,000 | -0.9% | 73,452 | -2.5% | 0.07% | -4.0% |
| Q2 2017 | $6,359,000 | -15.9% | 75,358 | -14.7% | 0.08% | -15.7% |
| Q1 2017 | $7,557,000 | -0.4% | 88,361 | -9.4% | 0.09% | -4.3% |
| Q4 2016 | $7,589,000 | +1.3% | 97,488 | +2.0% | 0.09% | -4.1% |
| Q3 2016 | $7,489,000 | -21.9% | 95,537 | +0.6% | 0.10% | -21.8% |
| Q2 2016 | $9,588,000 | -1.0% | 94,930 | -7.0% | 0.12% | -3.1% |
| Q1 2016 | $9,682,000 | -24.1% | 102,066 | -25.7% | 0.13% | -25.1% |
| Q4 2015 | $12,755,000 | +1.3% | 137,326 | -7.0% | 0.17% | -4.5% |
| Q3 2015 | $12,586,000 | -10.5% | 147,710 | -10.1% | 0.18% | -4.3% |
| Q2 2015 | $14,067,000 | -20.4% | 164,356 | -21.1% | 0.19% | -17.6% |
| Q1 2015 | $17,674,000 | -19.0% | 208,179 | -18.2% | 0.23% | -19.8% |
| Q4 2014 | $21,816,000 | -42.6% | 254,533 | -49.1% | 0.28% | -40.3% |
| Q3 2014 | $37,979,000 | -2.9% | 499,858 | +0.6% | 0.47% | -1.0% |
| Q2 2014 | $39,132,000 | +4.3% | 497,047 | -0.6% | 0.48% | +0.6% |
| Q1 2014 | $37,520,000 | -2.5% | 500,272 | +0.3% | 0.48% | 0.0% |
| Q4 2013 | $38,494,000 | +5.0% | 498,629 | -5.7% | 0.48% | -1.9% |
| Q3 2013 | $36,671,000 | +10.1% | 529,001 | +0.5% | 0.48% | +6.8% |
| Q2 2013 | $33,309,000 | – | 526,199 | – | 0.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |